News
Antibody drug moves to phase 3 trials
Phase three trials are in the works for a combination antibody treatment for Covid-19.
Monday, July 6th 2020, 11:47 AM CDT
Updated:
Phase three trials are in the works for a combination antibody treatment for Covid-19.
That's according to a Monday announcement from bio-tech company Regeneron.
The drug is called REGNCOV-2.
Late-stage clinical trials will evaluate the drug's ability to prevent infection in people who have had close contact with an infected person.
The prevention trial takes place at roughly 100 sites and is expected to include 2,000 US patients.
It's also being tested for its ability to treat patients who are already infected with Covid-19.
Those trials are set to include more than 1,800 hospitalized patients and upwards of 1,000 non-hospitalized patients.
They are expected to take place at 150 sites in the US, Brazil, Mexico and Chile.